Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome - TRACER


Protease-activated receptor 1 (PAR-1) activation by thrombin is one of the most potent stimulators of platelet activation. The current trial sought to study the safety and efficacy of vorapaxar, a novel PAR-1 antagonist, in patients with recent acute coronary syndrome (ACS).